{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:15:47Z","timestamp":1780337747094,"version":"3.54.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Limited information is available on patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) receiving mycophenolate mofetil (MMF) in Japan. The dose, treatment duration, and patient characteristics of SSc and SSc-ILD patients receiving MMF were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used data from a Japanese hospital claims database (2008\u20132020).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data on 486 SSc patients \u226518\u2009years old receiving MMF were captured; 314 had SSc complicated with ILD. The most common initial daily doses were 1000\u2009mg (SSc, 39.5%; SSc-ILD, 38.1%) and 500\u2009mg (SSc, 36.6%; SSc-ILD, 34.6%). The most common maximum daily doses were 1000\u2009mg (SSc, 33.3%; SSc-ILD, 34.9%), 1500\u2009mg (SSc, 24.4%; SSc-ILD, 23.1%), and 2000\u2009mg (SSc, 23.8%; SSc-ILD, 24.4%). Doses ranged from 250 to 3000\u2009mg\/day and were similar for SSc and SSc-ILD patients. Over 27% of patients received treatment for &amp;gt;1\u2009year. There was a gradual decrease in steroid doses during MMF treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study suggests that the off-label use of MMF for SSc and SSc-ILD has been increasing annually since 2015 in Japan. The doses used in patients with SSc and SSc-ILD were similar to the approved doses of MMF for lupus nephritis in Japan.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab111","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:20:06Z","timestamp":1638343206000},"page":"755-760","source":"Crossref","is-referenced-by-count":5,"title":["Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database"],"prefix":"10.1093","volume":"32","author":[{"given":"Takashi","family":"Funatogawa","sequence":"first","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Narita","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Tamura","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Mii","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Sugitani","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"2022070111365742600_R1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2022070111365742600_R2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2022070111365742600_R3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022070111365742600_R4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2022070111365742600_R5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022070111365742600_R6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10067-013-2289-0","article-title":"Mortality in systemic sclerosis\u2014a single centre study from the UK","volume":"32","author":"Strickland","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2022070111365742600_R7","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"key":"2022070111365742600_R8","author":"Japan Intractable Diseases Information Center (in Japanese)","year":"2021"},{"key":"2022070111365742600_R9","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2022070111365742600_R10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/ard.42.4.368","article-title":"The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up","volume":"42","author":"Baltus","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"2022070111365742600_R11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022070111365742600_R12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"2022070111365742600_R13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2022070111365742600_R14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2022070111365742600_R15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/rheumatology\/keaa547","article-title":"Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022070111365742600_R16","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"SENSCIS trial investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2022070111365742600_R17","author":"Medical Data Vision Co., Ltd","year":"2021"},{"key":"2022070111365742600_R18","article-title":"Statement on the use of Mycophenolate Mofetil for Lupus Nephritis (in Japanese)","author":"Japan College of Rheumatology, Japanese Society of Nephrology, Pediatric Rheumatology Association of Japan, Japanese Society for Pediatric Nephrology","year":"2015"},{"key":"2022070111365742600_R19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/14397595.2015.1031444","article-title":"Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan","volume":"25","author":"Yasuda","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2022070111365742600_R20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.14162","article-title":"Diagnostic criteria, severity classification and guidelines of systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol"},{"key":"2022070111365742600_R21","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2022070111365742600_R22","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022070111365742600_R23","article-title":"The guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease (in Japanese)","author":"The Japanese Respiratory Society, Japan College of Rheumatology","year":"2020"},{"key":"2022070111365742600_R24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.resinv.2017.11.004","article-title":"Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis","volume":"56","author":"Ueda","year":"2018","journal-title":"Respir Investig"},{"key":"2022070111365742600_R25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.31138\/mjr.30.1.33","article-title":"Treatment of systemic sclerosis associated fibrotic manifestations: current options and future directions","volume":"30","author":"Daoussis","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"2022070111365742600_R26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17476348.2019.1575732","article-title":"Scleroderma-related interstitial lung disease: principles of management","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"2022070111365742600_R27","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab111\/41699488\/roab111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/4\/755\/44366671\/roab111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/4\/755\/44366671\/roab111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T11:38:15Z","timestamp":1656675495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/4\/755\/6444226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,11,26]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab111","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,11,26]]}}}